Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1964
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1972 1
1976 1
1977 1
1979 1
1981 1
1984 2
1987 1
1988 2
1989 1
1990 4
1991 2
1992 3
1993 1
1995 10
1996 4
1997 10
1998 5
1999 7
2000 11
2001 13
2002 9
2003 8
2004 10
2005 4
2006 5
2007 13
2008 7
2009 7
2010 12
2011 15
2012 10
2013 24
2014 28
2015 14
2016 12
2017 13
2018 7
2019 16
2020 24
2021 15
2022 40
2023 46
2024 21
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

410 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-associated macrophages in liver cancer: From mechanisms to therapy.
Cheng K, Cai N, Zhu J, Yang X, Liang H, Zhang W. Cheng K, et al. Cancer Commun (Lond). 2022 Nov;42(11):1112-1140. doi: 10.1002/cac2.12345. Epub 2022 Sep 7. Cancer Commun (Lond). 2022. PMID: 36069342 Free PMC article. Review.
In addition, macrophages and liver cancer cells have distinct origins. At the early stage of liver cancer, macrophages can provide a niche for the maintenance of liver cancer stem cells. ...Despite the latest achievements and the advancements in treatment str …
In addition, macrophages and liver cancer cells have distinct origins. At the early stage of liver cancer, macrophages can pro …
Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Ilyas SI, Gores GJ. Ilyas SI, et al. Gastroenterology. 2013 Dec;145(6):1215-29. doi: 10.1053/j.gastro.2013.10.013. Epub 2013 Oct 15. Gastroenterology. 2013. PMID: 24140396 Free PMC article. Review.
Cholangiocarcinomas (CCAs) are hepatobiliary cancers with features of cholangiocyte differentiation; they can be classified anatomically as intrahepatic CCA (iCCA), perihilar CCA (pCCA), or distal CCA. These subtypes differ not only in their anatomic location, but in epide …
Cholangiocarcinomas (CCAs) are hepatobiliary cancers with features of cholangiocyte differentiation; they can be classified anatomically as …
Clinical treatment of cholangiocarcinoma: an updated comprehensive review.
Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, Cristoferi L, Ciaccio A, Cortinovis DL, Invernizzi P, Massironi S. Elvevi A, et al. Ann Hepatol. 2022 Sep-Oct;27(5):100737. doi: 10.1016/j.aohep.2022.100737. Epub 2022 Jul 7. Ann Hepatol. 2022. PMID: 35809836 Free article. Review.
Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms of the bile ducts and represents the second most common hepatic cancer after hepatocellular carcinoma; it is sub-classified as intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarc …
Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms of the bile ducts and represents the second most common hepatic cancer after …
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
Sia D, Villanueva A, Friedman SL, Llovet JM. Sia D, et al. Gastroenterology. 2017 Mar;152(4):745-761. doi: 10.1053/j.gastro.2016.11.048. Epub 2016 Dec 30. Gastroenterology. 2017. PMID: 28043904 Free article. Review.
We review hypotheses of the cell of origin of liver tumorigenesis and clarify the classes of liver cancer based on molecular features and how they affect patient prognosis. Primary liver cancer comprises hepatocellular carcinoma (HCC), intrah
We review hypotheses of the cell of origin of liver tumorigenesis and clarify the classes of liver cancer based on molecular f …
Cholangiocarcinoma.
Sarcognato S, Sacchi D, Fassan M, Fabris L, Cadamuro M, Zanus G, Cataldo I, Capelli P, Baciorri F, Cacciatore M, Guido M. Sarcognato S, et al. Pathologica. 2021 Jun;113(3):158-169. doi: 10.32074/1591-951X-252. Pathologica. 2021. PMID: 34294934 Free PMC article. Review.
Liver cancer represents the third leading cause of cancer-related death worldwide. Cholangiocarcinoma (CCA) is the second most common type of liver cancer after hepatocellular carcinoma, accounting for 10-15% of all primary liver malignancies. .
Liver cancer represents the third leading cause of cancer-related death worldwide. Cholangiocarcinoma (CCA) is the second most common
Metabolic reprogramming and its clinical implication for liver cancer.
Yang F, Hilakivi-Clarke L, Shaha A, Wang Y, Wang X, Deng Y, Lai J, Kang N. Yang F, et al. Hepatology. 2023 Nov 1;78(5):1602-1624. doi: 10.1097/HEP.0000000000000005. Epub 2023 Jan 3. Hepatology. 2023. PMID: 36626639 Free PMC article. Review.
HCC and cholangiocarcinoma (CCA) are 2 different liver cancers with high intertumoral heterogeneity in terms of etiologies, mutational landscapes, transcriptomes, and histological representations. ...We discuss metabolism of NAFLD as well, because NAFLD will likely become …
HCC and cholangiocarcinoma (CCA) are 2 different liver cancers with high intertumoral heterogeneity in terms of etiologies, mutationa …
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice.
Pinter M, Scheiner B, Pinato DJ. Pinter M, et al. Lancet Gastroenterol Hepatol. 2023 Aug;8(8):760-770. doi: 10.1016/S2468-1253(23)00147-4. Epub 2023 Jun 14. Lancet Gastroenterol Hepatol. 2023. PMID: 37327807 Review.
Systemic therapy for advanced hepatocellular carcinoma has expanded at an unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the field for more than a decade, immune checkpoint inhibitor (ICI)-based therapies have become the main co …
Systemic therapy for advanced hepatocellular carcinoma has expanded at an unprecedented pace over the past 5 years. After tyro …
Fibroblasts in liver cancer: functions and therapeutic translation.
Affo S, Filliol A, Gores GJ, Schwabe RF. Affo S, et al. Lancet Gastroenterol Hepatol. 2023 Aug;8(8):748-759. doi: 10.1016/S2468-1253(23)00111-5. Epub 2023 Jun 26. Lancet Gastroenterol Hepatol. 2023. PMID: 37385282 Free article. Review.
Hepatocellular carcinoma is a largely non-desmoplastic tumour, in which fibroblasts accumulate predominantly in the pre-neoplastic fibrotic liver and regulate the risk for hepatocellular carcinoma development through a balance of tumour-suppress
Hepatocellular carcinoma is a largely non-desmoplastic tumour, in which fibroblasts accumulate predominantly in the pre-neopla
FGFR2 Inhibition in Cholangiocarcinoma.
Vogel A, Segatto O, Stenzinger A, Saborowski A. Vogel A, et al. Annu Rev Med. 2023 Jan 27;74:293-306. doi: 10.1146/annurev-med-042921-024707. Epub 2022 Sep 28. Annu Rev Med. 2023. PMID: 36170665 Free article. Review.
Biliary tract cancer (BTC) is the second most common primary liver cancer after hepatocellular carcinoma and accounts for 2% of cancer-related deaths. BTCs are classified according to their anatomical origin into intrahepatic (iCCA), peri
Biliary tract cancer (BTC) is the second most common primary liver cancer after hepatocellular carcinoma
Pathology of Cholangiocarcinomas.
Guedj N. Guedj N. Curr Oncol. 2022 Dec 26;30(1):370-380. doi: 10.3390/curroncol30010030. Curr Oncol. 2022. PMID: 36661679 Free PMC article. Review.
Cholangiocarcinomas (CCA) are heterogeneous tumors that arise from epithelial cells of the biliary tract. They represent the second primary liver malignancy, after hepatocellular carcinoma. Recent epidemiological data show an increased incidence …
Cholangiocarcinomas (CCA) are heterogeneous tumors that arise from epithelial cells of the biliary tract. They represent the s …
410 results